Receipt of Section 249D Notice from BCAL Diagnostics
Filed with ASX · · 1 page · English
Summary by 6ix AI
The company is currently evaluating the validity of this notice and will comply with its obligations under the Corporations Act if deemed valid. This announcement is made in accordance with ASX Listing Rule requirements.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Genetic Signatures' latest callGenetic Signatures (ASX:GSS) Q4 2026 Earnings Call · Replay · Aug 25Read the transcript of Genetic Signatures (ASX:GSS) Q4 2026 Earnings CallGenetic Signatures Ltd. on 6ix
Story so far
Earlier from Genetic Signatures
- BDX Holdings of GSS Shares and receipt of Section 249D
- Genetic Signatures and Microba in Merger Discussions
- FY26 Market Update
- GSS responds to the BCAL Diagnostics Announcement
- BCAL to Acquire Shares in Genetic Signatures
Later from Genetic Signatures
- GSS Investor Presentation - Proposed Merger with MAP
- Quarterly Activities/Appendix 4C Cash Flow Report
- GSS: Response to Media Speculation & BCAL letter to GSS
- Response to Media Speculation & BCAL letter to GSS
- Update on Commercial Terms for Proposed Merger with MAP
Follow Genetic Signatures into a list and get an email when it puts out news.
Follow Genetic Signatures